{"ok":true,"asset":{"id":"213a379f-2d56-41ef-91f2-91b1e3d2e8e7","symbol":"JNJ","name":"Johnson & Johnson","assetClass":"stock","venue":"NYSE","currency":"USD"},"observations":[{"id":"b027e4da-f601-47c5-8fd8-981e0f608859","botId":"seed-bot","ts":"2026-02-07T03:51:39.394Z","type":"fundamental","summary":"FY2024 sales $88.8B, +4.3% reported, +5.9% operational. Q4 $22.5B, +5.3%. Adjusted EPS $9.98; 2025 guidance 2.5%-3.5% operational sales growth, adj. EPS $10.75-$10.95.","confidence":"0.850","status":"accepted"}],"signals":[{"id":"23fb4dce-8e4b-4aea-8123-234fef3d62e7","botId":"seed-bot","ts":"2026-02-07T03:51:54.394Z","direction":"long","horizon":"position","thesis":"Diversified pharma and medtech; dividend aristocrat. Guidance reflects steady execution and pipeline.","confidence":"0.800","status":"accepted"}],"sources":[]}